title: [Management of pulmonary circulation alterations].
authors.affiliation: Servicio de Cardiología Pediátrica, Hospital Ramón y Cajal, Madrid.
authors.forename: M C
authors.initials: MC
authors.lastname: Quero Jiménez
authors.forename: M
authors.initials: M
authors.lastname: Burgueros Valero
authors.forename: C
authors.initials: C
authors.lastname: González Dieguez
authors.forename: F
authors.initials: F
authors.lastname: Domínguez Pérez
authors.forename: J
authors.initials: J
authors.lastname: Pinto Corraliza
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez Fernández
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007231:Infant, Newborn; D007511:Ischemia / Q000503:physiopathology; D007650:Ketanserin / Q000627:therapeutic use; D008168:Lung / Q000098:blood supply; D009569:Nitric Oxide / Q000627:therapeutic use; D010100:Oxygen / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D011458:Prostaglandins E / Q000627:therapeutic use; D011652:Pulmonary Circulation / Q000502:physiology*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D011458:Prostaglandins E; D014665:Vasodilator Agents; D009569:Nitric Oxide; D007650:Ketanserin; D010100:Oxygen
vernacular_title: Manejo de las alteraciones de la circulación pulmonar.